Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in Advanced Mycosis Fungoides
NCT03695471Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Feb 2020
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by Mayo Clinic. Primary endpoint: Proportion of Overall Cutaneous Responders at Their 9th or Final Cycle at 7 months. Started Feb 2020; status: completed.
02
Drugs
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT03695471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03695471.